ebmt activity survey 2017 · 2019-09-03 · march 2019 ebmt activity survey in 2017: donor type and...
TRANSCRIPT
www.ebmt.org
EBMT Activity Survey 2017683 Teams
41,100 Patients45,418 Transplants
49 CountriesFor internal use only.
For any other use, please contact Helen Baldomero for permission: [email protected]
Provided by the EBMT Activity Survey Office: not for publication
March 2019
EBMT Activity Survey in 2017: Patient and transplant numbers
Allogeneic
HSCT
Autologous
HSCT Total
1st allo/1st auto HSCT
Additional HSCT
TOTAL
Teams: 683 (of 710) Countries reporting: 49
17,155
1,126
18,281
23,945
3,192
27,137
41,100
4,318
45,418
Indication
March 2019
EBMT Activity Survey in 2017: Donor type and stem cell source: all transplants
BM PBSC
HLA-id sibling
Haplo-identical
Other family
Syngeneic
Unrelated
Allogeneic
Autologous
1,420
708
89
n.a.
1,492
3,709
112
5,864
2,689
306
21
9,401
18,281
27,137
Total
4,411
1,981
212
n.a.
7,579
14,204
27,022
Donor type
Stem Cell Source
Cord
33
n.a.
5
n.a.
330
368
3
March 2019
EBMT Activity Survey 2017:Main indications
Allogeneic
1st HSCT
Autologous
1st HSCT Total
Myeloid (AML, CML, MDS/MPN)
Lymphoid (ALL, CLL, HL, NHL)
Plasma cell disorder
Solid tumor
Non-malignant disorders
bone marrow failure
Other
Total Patients
9,772
4,630
385
36
2,173
802
159
17,155
375
8,781
12,692
1,571
494
1
32
23,945
10,147
13,411
13,077
1,607
2,667
803
191
41,100
Indication
March 2019
Allogeneic HSCT in Europe 20171st HSCT
AML, 39%
CML, 2%
MDS, 12%MPN, 4%
ALL, 16%
CLL, 1%
PCD, 2%
HL, 3%
NHL, 7.5%
Solid tumors, 0.2%
BMF, 5%
HG, 4%
PID, 3%IDM, 0.9%
AID, 0.1%
Others, 1%
Provided by the EBMT Activity Survey Office: not for publication
March 2019
Autologous HSCT in Europe 20171st HSCT
Myeloid disorders, 2%
ALL/CLL, 0.4%
PCD, 53%
HL, 9%
NHL, 27%
Neuroblastoma, 2%
Soft tissue/Ewing, 1%
Germinal tumors , 2%
Breast, 0.1%
Other ST, 2% NMD, 0.1%
AID, 2%
Others , 0.1%
Provided by the EBMT Activity Survey Office: not for publication
March 2019
HSCT Activity in Europe 1990-2017:Transplant type 1st HSCT
Provided by the EBMT Activity Survey Office: not for publication
March 2019
HSCT Activity in Europe 1990-2017:Main indications: allogeneic 1st. HSCT
Provided by the EBMT Activity Survey Office: not for publication
March 2019
HSCT Activity in Europe 1990-2017:Main indications: autologous 1st. HSCT
Provided by the EBMT Activity Survey Office: not for publication
March 2019
HSCT Activity in Europe 1990-2017:donor origin: 1st. HSCT
Provided by the EBMT Activity Survey Office: not for publication
March 2019
HSCT - rates in Europe 2017
N. allogeneic transplants
per 10 million population
0 or no report
0.1 - 100
101 - 150
151 – 200
201 – 300
> 300
Algeria, Iran, Iraq, Lebanon, Nigeria, South Africa, Tunisia
Jordan, Saudi Arabia
Israel
Provided by the EBMT Activity Survey Office: not for publication
March 2019
HSCT - rates in Europe 2017
N. autologous transplants
per 10 million population
0 or no report
1 - 100
101 - 300
301 – 400
401 – 500
> 500
Algeria, Iran, Iraq, Jordan, Lebanon, Saudi Arabia, South Africa,
Tunisia
Israel
Provided by the EBMT Activity Survey Office: not for publication